Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Anti-OX40 Antibody KHK4083 in Moderate to Severe Atopic Dermatitis
jRCT2080224054Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of rocatinlimab in atopic dermatitis (AD) (5 arms), sponsored by Kyowa Kirin. Started Sep 2018; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224054.